MASH

The AJMC® metabolic dysfunction-associated steatohepatitis compendium is a comprehensive resource for clinical news and expert insights for the condition, which was formerly known as nonalcoholic steatohepatitis.

Latest News
July 1st 2025

Surgeries and Endoscopic Procedures Offer Different Benefits for MASLD

June 28th 2025

Weight Loss Drug HU6 Shows Promise in MASH With Muscle-Sparing Benefits

June 20th 2025

Air Pollution, Obesity Linked to Significant Liver Fibrosis in Patients With MASH

June 12th 2025

Alarming Rise in Liver Disease Amid Global Fatty Liver Day 2025

June 2nd 2025

Calorie Consumption Tied to Mortality Risk in Men With MASLD

Video Interviews
View All
May 6th 2025

Early Identification of MASLD/MASH Saves Lives: Naim Alkhouri, MD

April 24th 2025

Increased Awareness, Novel Interventions Spell New Era for MASLD/MASH: Naim Alkhouri, MD

April 17th 2025

New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD

More News

Patient injecting semaglutide | Image credit: Lana Pietukhova – stock.adobe.com
May 12th 2025

Semaglutide May Reduce Liver Fibrosis in Patients With MASH

Hayden E. Klein
Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared with placebo.
Naim Alkhouri, MD
May 9th 2025

Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD

Kyle Munz Naim Alkhouri, MD
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Patients with metabolic dysfunction-associated steatohepatitis carry an increased risks for cardiovascular disease and related events | image credit: reyanking999 - stock.adobe.com
April 15th 2025

Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH

Kyle Munz
A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Outside of liver fibrosis improvements, pegbelfermin also significantly improved MASH vs placebo. | Image credit: filins - stock.adobe.com
April 14th 2025

Pegbelfermin Shows Promise in Addressing Liver Fibrosis in MASH

AJMC Contributor
Data from patients across 3 different randomized controlled trials showed improvements in both adiponectin and PRO-C3, primary end points in the trials.
MASLD significantly increases the risk of severe infection, a literature review suggests. | Image credit: SewcreamStudio - stock.adobe.com
April 12th 2025

MASLD Associated With 2-Fold Increase of Serious Bacterial Infection

AJMC Contributor
Data from a meta-analysis of 8 observational studies accounting for more than 26 million people across the globe were evaluated in a new review.
GLP-1s benefit patients with numerous conditions, including diabetes, cardiovascular disease, obsesity, and more | Ishika - stock.adobe.com
March 27th 2025

GLP-1 RAs May Offer Broad Hepatic Benefits in MASH

Kyle Munz
Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver health benefits independent of this mechanism.
The FDA approval of resmetirom approval has “profound implications” for the care of MASLD and MASH because it allows those conditions to be managed with a liver-specific therapy in addition to lifestyle modifications. | Image credit: Nisit - stock.adobe.com
March 25th 2025

New Therapies Expanding the MASH Treatment Landscape

Jared Kaltwasser
Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.
The authors explained that underrepresentation of certain groups and countries in MASH clinical trials can be addressed through better collaboration and novel methodologies. | Image credit: Jo Panuwat D - stock.adobe.com
March 24th 2025

MASH Clinical Trials Historically Underrepresent Certain Groups

Jared Kaltwasser
Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated steatohepatitis (MASH) still take place in high-income countries and have majority-White patient populations.
Lipid metabolite assays could be a potential noninvasive diagnostic alternative for patients with MASH who otherwise may need a liver biopsy | image credit: Vlad - stock.adobe.com
March 13th 2025

Lipid Metabolites Emerge as Noninvasive Diagnostic Tool in MASH

Kyle Munz
The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic methods for metabolic dysfunction–associated steatohepatitis (MASH).
Doctor holding a glass globe | Image credit: natali_mis - stock.adobe.com
March 2nd 2025

Mortality Declines but Incidence Rates Up for Cirrhosis and Other Chronic Liver Diseases

Laura Joszt, MA
Rising rates of metabolic dysfunction–associated steatohepatitis indicate a need for public health interventions.
At 2 years, participants in the compensated MASH cirrhosis treatment arm experienced a statistically significant reduction in liver stiffness from baseline. | Image Credit: Peakstock - stock.adobe.com
February 27th 2025

Resmetirom Reduces Liver Stiffness in MASH-Compensated Cirrhosis

Rose McNulty
At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.
cirrhosis | image credit: eranicle - stock.adobe.com
February 24th 2025

Efruxifermin Reverses MASH-Compensated Cirrhosis in Phase 2b SYMMETRY Study

Abigail Brooks, MA
Preliminary topline week 96 results showed statistically significant reversal of metabolic dysfunction–associated steatohepatitis (MASH)–compensated cirrhosis with efruxifermin in complete and intent-to-treat analyses.
Fibroblast growth factor 21 | image credit: Juan Gärtner - stock.adobe.com
February 19th 2025

Promising Potential for FGF21 Analogs in MASH Management

Kyle Munz
Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
MASH-related PLC is on the rise in young adult populations, causing concerns about how to best address the metabolic disease epidemic | image credit: https://gencraft.com/generate
February 6th 2025

MASH-Related PLC on the Rise in Young Adults

Kyle Munz
As a growing number of young adults with primary liver cancer (PLC) related to metabolic dysfunction–associated steatohepatitis (MASH) age, developing coherent strategies to combat the metabolic disease epidemic is critical.
The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics | image credit: TAW4 - stock.adobe.com
January 28th 2025

"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000

Kyle Munz
The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.
The management of MASH for those on a GLP-1RA could benefit from the edition of efruxifermin | image credit: Crystal Light - stock.adobe.com
January 27th 2025

Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes

Kyle Munz
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition of efruxifermin.
MASH is the inflammatory, progressed form of MASLD | image credit: Rasi - stock.adobe.com
January 20th 2025

A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins

Kyle Munz
Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver disease (MASLD).
Man holding liver illustration - SewcreamStudio - stock.adobe.com
June 12th 2024

Study Highlights Increasing Global Health Burden of Liver Cancer

Rose McNulty
The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.
Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com
March 14th 2024

FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

Laura Joszt, MA
The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
doctor checking liver
October 11th 2022

ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments

Laura Joszt, MA
There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.
fatty liver
November 23rd 2021

Improving Early Detection of Nonalcoholic Steatohepatitis on Ultrasound

Rose McNulty
A recent study aims to improve evaluation of fatty liver in ultrasound scans to increase hepatology referrals and predict significant liver fibrosis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo